Sandoz Reports Strong H1 2026 Financial Results

Sandoz Group AG, a leader in affordable medicines, announced robust financial outcomes for H1 2026. Net sales rose 5% at constant currencies to USD 5.761 billion. This growth was fueled primarily by biosimilars, which saw a 20% increase at constant currencies. Biosimilars accounted for a record 33% of total net sales, with North American sales soaring 47%.

Overall, the company's core EBITDA climbed 15%, enhancing the core-EBITDA margin to 20.9%. The second quarter highlighted a 7% rise in net sales, led by a 22% growth in biosimilars and a 1% return to growth for generics. Sandoz's trajectory appears positive, with continual investment in long-term growth and an expanding biosimilar pipeline.

Looking ahead, Sandoz confirmed its 2026 guidance, anticipating mid-to-high single-digit growth in net sales at constant currencies. The firm remains focused on strengthening its biosimilar platform and reducing its environmental impact, targeting significant reductions in emissions by 2035.